Barclays
CLYM

Barclays’s Climb Bio CLYM Stock Holding History

Barclays’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
26,924
-22,012
-45% -$227K ﹤0.01% 3397
2026
Q1 		$335K Sell
48,936
-12,917
-21% -$74.5K ﹤0.01% 3412
2025
Q4 		$247K Buy
61,853
+37,100
+150% +$89.1K ﹤0.01% 4209
2025
Q3 		$49.8K Sell
24,753
-4,624
-16% -$8.59K ﹤0.01% 4771
2025
Q2 		$36.4K Sell
29,377
-29,353
-50% -$36.5K ﹤0.01% 4752
2025
Q1 		$71.7K Buy
58,730
+8,926
+18% +$14.5K ﹤0.01% 4509
2024
Q4 		$89.6K Buy
49,804
+10,945
+28% +$39.6K ﹤0.01% 4618
2024
Q3 		$198K Buy
38,859
+36,316
+1,428% +$257K ﹤0.01% 4301
2024
Q2 		$18.1K Buy
+2,543
New +$16.9K ﹤0.01% 4451
2022
Q2 		– Sell
-2,850
Closed -$24K – 5317
2022
Q1 		$24K Buy
+2,850
New +$26.6K ﹤0.01% 4396

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's CLYM Position: Q2 2026 in Review

Barclays reduced its Climb Bio (CLYM) stake by 45% in Q2 2026, selling an estimated $227K and leaving 26,924 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

Barclays first reported a position in CLYM in Q1 2022 and has held it in 10 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Barclays held 26,924 shares of Climb Bio worth $351K as of Q2 2026.
  • Barclays sold 22,012 Climb Bio shares in Q2 2026, an estimated $227K.
  • Climb Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3397 holding.
  • Barclays first reported a position in Climb Bio in Q1 2022 and has held it in 10 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.